FDA Deems Longeveron's ELPIS II Trial Non-Pivotal, Citing Inappropriate Primary Endpoint

summarizeSummary

Longeveron announced that the FDA no longer considers its Phase 2b ELPIS II trial for HLHS pivotal, stating the primary endpoint is inappropriate, significantly increasing regulatory uncertainty for its lead candidate.

check_boxKey Events

• FDA Deems Trial Non-Pivotal

  The FDA informed Longeveron that its Phase 2b ELPIS II clinical trial for Hypoplastic Left Heart Syndrome (HLHS) is no longer considered pivotal.

• Primary Endpoint Deemed Inappropriate

  The FDA asserted that the trial's primary endpoint, right ventricle ejection fraction (RVEF), is not appropriate to demonstrate efficacy, a point Longeveron agreed with.

• No New Endpoint During Ongoing Trial

  Due to an NIH-mandated interim analysis, a new primary endpoint could not be agreed upon while the trial is still ongoing.

• Regulatory Uncertainty Increased

  This significantly raises regulatory risk for laromestrocel, Longeveron's lead investigational therapy, despite the FDA's willingness to meet post-trial completion.

auto_awesomeAnalysis

This 8-K reveals a critical setback for Longeveron's lead clinical program, ELPIS II, for HLHS. The FDA's determination that the trial is no longer pivotal due to an inappropriate primary endpoint creates substantial regulatory risk and uncertainty regarding the path to market for laromestrocel. While the FDA is open to future discussions and the company plans to submit a revised statistical analysis plan, the inability to agree on a new primary endpoint while the trial is ongoing is a significant hurdle. This negative development comes at a challenging time for Longeveron, which recently disclosed going concern doubts in its 10-K and is pursuing a reverse stock split to maintain its Nasdaq listing. Investors should monitor the company's revised SAP submission and the anticipated top-line results in August 2026 for any potential path forward, but the immediate outlook is significantly clouded.